Abstract #M422

# M422
Evaluation of three rumen-protected lysine sources produced in two different batches using a modified three-step in vitro procedure.
Haley E. Larson*1, Izuru Shinzato2, Makoto Miura3, Samuel W. Fessenden1, Isaac J. Salfer1, Marshall D. Stern1, 1University of Minnesota, Saint Paul, MN, 2Ajinomoto Heartland, Inc, Chicago, IL, 3Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc, Kawasaki, Japan.

A standardized 3-step in vitro procedure for evaluating rumen-protected lysine (RPL) sources was modified by Ajinomoto Co. Inc. and the University of Minnesota to estimate bioavailability of lysine within RPL products. The objective of this study was to evaluate variation between batch and source of RPL products AjiPro-L (A) and 2 other commercial products (B and C). Each RPL product was replicated 3 times in 3 runs to evaluate consistency of results within and between runs using the procedure. One gram of product from each RPL source, taken from one of 2 batches (2013, 2014) was individually weighed into a Dacron polyester bag. Bags were incubated in media bottles in a shaking water bath at 39?C for 30 h. Simulation of ruminal (20 h), abomasal (2 h) and intestinal (8 h) digestion was accomplished by immersing solutions at 20, 22 and 30 h. At each time point, a 10 mL aliquot of buffer was collected and analyzed for lysine concentration using a Bioflow BF-7 biosensor (Oji Scientific Instruments Co., Ltd., Japan). Statistical differences (P < 0.05) were identified using a one-way ANOVA. Differences (P < 0.001) were observed between the 3 product sources for rumen insoluble lysine (RIL) and abomasal insoluble lysine (AIL). Intestinally available lysine (IAL) for product A differed from B and C (P < 0.001). Results showed variation between 2013 and 2014 batches of product sources A and B for RIL and IAL, and product sources B and C for AIL (P < 0.001). The release efficiency (RE) of RIL for each product source differed between years (P < 0.001). Within each run of the procedure, there was no variation observed between replicate samples (P > 0.05). Variation was observed between runs for RIL (P < 0.002), AIL (P < 0.001) and RE (P < 0.03), with no variation between IAL (P > 0.05). The modified 3-step procedure demonstrated differences between product types and batches within the same product source. The procedure was consistent between replicates of a run demonstrating its ability to compare differences in bioavailability of RPL products.

Key Words: in vitro, rumen-protected lysine